43 / 86
Eribulin (n=226)
n (%)
Dacarbazine (n=224)
n (%)
Any grade
Grade ≥3
Any grade
Grade ≥3
Patients with any AEs
224 (99.1)
152 (67.3)
218 (97.3)
126 (56.3)
Neutropenia
99 (43.8)
80 (35.4)
53 (23.7)
35 (15.6)
Fatigue
99 (43.8)
7 (3.1)
86 (38.4)
3 (1.3)
Nausea
91 (40.3)
2 (0.9)
106 (47.3)
1 (0.4)
Alopecia
79 (35.0)
–
6 (2.7)
–
Constipation
71 (31.4)
2 (0.9)
58 (25.9)
1 (0.4)
Anemia
67 (29.6)
16 (7.1)
69 (30.8)
27 (12.1)
Pyrexia
63 (27.9)
2 (0.9)
31 (13.8)
1 (0.4)
Asthenia
47 (20.8)
4 (1.8)
51 (22.8)
7 (3.1)
Peripheral sensory neuropathy
46 (20.4)
4 (1.8)
8 (3.6)
–
Thrombocytopenia
13 (5.8)
1 (0.4)
62 (27.7)
34 (15.2)
Schöffski P, et al. Presented at ASCO 2015 Annual Meeting, Chicago IL, June 3-7, 2015:abstr LBA10502